Pulse™: Cell line development from design to GMP master cell bank

Driving faster, clinically aligned iPSC cell line development with clean IP.

Pulse designer image
Group 35380

Setting the standard in cell line development.

Pulse™ enables cell therapy innovators to simplify and accelerate the journey from iPSC line to GMP Master Cell Bank — uniting cell line design, reprogramming, gene editing, and GMP master cell banking (MCB) under one integrated platform with transparent, proprietary IP.

Drug Developer Pain Point Cellistic Solution
Speed & Safety

Traditional editing approaches can add up to 6 months per edit to development and increase risks to genomic integrity.

Cut 12+ months of your timeline

Checkmark IconSTAR-CRISPR™ multiplexing enables up to 4 gene edits in a single shot

Checkmark Icon

Automated high-throughput clonal selection with C.Station & UP.Sight

Clear IP Positioning

Licensing complexity and unclear IP hinder path to commercialization.

Integrated IP and licensing 

Checkmark Icon

All IP - including STAR-CRISPR™ and unedited and edited Allo Chassis™ lines-under one roof 

Regulatory Readiness

Advancing with confidence in a comparatively new regulatory environment.

Regulatory-ready from day one

Checkmark Icon

Rigorous QC/QA with low-passage banking ensures genomic stability, reproducibility, and monoclonality

Checkmark Icon

GMP Master Cell Banks, produced in an EMA-certified, FDA/PMDA-compliant facility

True End-to-End Continuity

Fragmented handoff between Cell Line Development and Manufacturing lead to rework, lost time, and added risk.

End-to-end continuity

Checkmark Icon

Seamless integration to GMP manufacturing of cell therapy drug product through our Cellistic Echo™ platform

What Pulse™ delivers.

Cut timelines by 12+ months with iPSC cell line deliverables optimized for clinical readiness and manufacturing continuity — here’s what that includes:

_65A9407_R 2 (1)

Fully characterized, GMP-compliant iPSC master cell bank

≥200 vials (≥1M cells each), low-passage and genomically stable.

Comprehensive documentation package 

Certificates of Analysis, Certificate of Compliance, traceability logs, clone histories, batch records.

Pre-validated release assays and QC panel 

streamlined handover to GMP manufacturing facility.

Proof of monoclonality

automated, image-based evidence of single-cell origin and full clone history for your regulatory file.

Off-target analysis data

characterization of your gene edits to support your safety assesment.

Pulse™: The integrated workflow for clinical-grade iPSCs.

Integrating scientific precision with operational scalability — and flexible enough to meet you at any stage of development.

GMP by design

Purpose-built iPSC GMP environment, pre-qualified assays, reagents and vendors, and QA oversight from day one.

Automation

C.Station & UP.Sight enable high-throughput screening for monoclonality, traceability, and optimal clone selection.

Owned IP: STAR-CRISPR™

Up to four simultaneous edits with high efficiency and minimal off-targets, fully owned by Cellistic, so there are no third-party licenses.

 

Integrated platform

Reprogramming, editing and banking in one facility, with Allo Chassis™ or custom lines and a seamless handover to Cellistic Echo™.

Pulse™ cell line development workflow: donor, reprogramming to an iPSC line, gene editing with STAR-CRISPR™ to an engineered clonal iPSC line, and GMP banking to a GMP master cell bank, with customer entry points at each stage.

Next: Cellistic Echo™: your GMP master cell bank becomes the starting material for differentiation into cell therapy drug product on our Cellistic Echo™ manufacturing platform. 

Release testing panel

Identity

STR

Microbiological safety

Sterility, mycoplasma, endotoxin and viral testing

Purity

Pluripotency marker expression

Impurities

Residual reprogramming components

Quantity

Cell count and viability

Genomic safety

Karyotype (ddPCR and G-banding), targeted NGS and WGS; edit verification for engineered lines

GMP master cell banking

A GMP master cell bank (MCB) is the single, fully characterized source of every future batch of your iPSC-derived therapy. Our turnkey process takes your selected clone through seed bank testing, GMP banking and release, with a full release testing panel and genomic safety assessment (see our WGS case study), providing the critical proof for your IND or CTA.

Checkmark IconEstablished GMP process for seed bank testing, manufacturing, cryopreservation, quality control and release, using pre-qualified materials

Checkmark Icon≥200 vials per MCB (≥1M cells each), low-passage, with an optional working cell bank to protect your master stock

Checkmark IconDelivered with the full GMP documentation package, including Certificate of Analysis and release data

Checkmark IconBank your own iPSC line or donor material, or start from one of our off-the-shelf GMP MCBs

Off-the-shelf iPSC cell lines & GMP master cell banks.

Non-edited

Origin Gene Editing GMP MCB
CD34+ T-Cell - GMP MCB
CD4+ T-Cell - -

 

Allo Chassis™ (Edited)

Origin Gene Editing GMP MCB
CD34+ T-Cell
Double KO
(MHC-I/II null)
GMP MCB

CD4+ T-Cell Double KO
(MHC-I/II null)
GMP MCB

 

_65A9407_R 3 (1)

Why Cellistic?

GMP manufacturing excellence

EMA-certified, FDA/PMDA-compliant GMP facility in Mont-Saint-Guibert (Belgium) combining industrialized processes and automation for consistent, clinical-grade manufacturing.

Enabling technologies

Proprietary platforms — Pulse™ and Cellistic Echo™, technologies STAR-CRISPR™ and Allo Chassis™ — combined with end-to-end CDMO services to accelerate allogeneic iPSC-derived therapy development.

15 years of iPSC expertise

With over 15 years of focused iPSC innovation, our scientists have refined differentiation, scale-up, and analytical strategies that define industry benchmarks for consistency, potency, and quality.

Quality & reliability

Rigorous QC/QA systems and advanced analytical methods ensure consistent, compliant, and high-performing cell therapy materials.



Frequently asked questions

 

Not finding what you’re looking for? Contact us.

Group 35320-2

Tune our platforms and technologies to your exact needs.

The next steps are clear: You learn more about our platforms and technologies (and the experienced team behind them). We talk about your immune oncology or regenerative medicine’s specific challenges and opportunities. And then together, we chart the ideal  path to advance your program to commercial success.